Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This information is incorrect. I use Charles Schwab and have not been able to buy IPIX since April 17.
I can no longer buy IPIX using Schwab:
"Your order cannot be accepted. This security IPIX is accepting closing transactions only. (DO911)"
Agreed. I likewise continue to accumulate shares.
No need to feel embarrassed. I've been investing in this company since 2013, & I am still gradually accumulating shares. Best wishes for your recovery. :)
I bought my 1st shares of CTIX in the summer of 2013. Holding my shares & buying more as I can.
I thought it was a glitch with my TD Ameritrade account.
Still in!
And thanks! ;)
Which = approximately $50/share, correct?
.53 hmmmm .........
PR - 04/09/2018
BioVie Attains Milestone
Company Reaches 50% Patient Enrollment in Phase 2a Clinical Trial of BIV201 for Refractory Ascites
BEVERLY, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it has achieved 50% enrollment of the patients in its open-label Phase 2a clinical study of BIV201 (continuous infusion terlipressin) for treating refractory ascites due to advanced liver cirrhosis.
Penny Markham, PhD, BioVie Chief Scientist, stated, "The patients we are targeting for BIV201 therapy are desperately ill and experience a miserable quality of life. Absent liver transplantation, their outcomes are very poor. We are pleased to be working on developing a novel drug candidate that could potentially improve their future."
BioVie is conducting a mid-stage (Phase 2a) clinical trial of its Orphan Drug candidate, BIV201 (continuous infusion terlipressin), which has FDA Fast Track status and US patent protection. This compound represents a potential new treatment for thousands of patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, NASH, and alcoholism. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The FDA has never approved a drug specifically for treating ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan.
Wow, 1hb! Now that's what I call impressive!
Thank you! I appreciate the commentary here. ;)
Any thoughts re. IPIX? Thank you!
Or Sales, perhaps?
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
FRAMINGHAM, MA -- (Marketwired) -- 06/06/17 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today presented a corporate update at the LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
"This has been an exciting period for Arch," said Terrence W. Norchi, President and CEO of Arch Therapeutics, Inc. "As previously announced, we expect to file for a 510(k) allowance mid-year for AC5™ designed for external use. If the 510(k) filing is allowed by the FDA, we expect that the benefit will be significant in terms of business opportunity and technology validation. We have invested significant time and effort into accelerating our plans for this regulatory application in the US, and we continue to concentrate resources on this objective. We are currently working to scale up production while evaluating and developing further indications. We expect to have commercial product available in 2018."
The 510(k) pathway enables Arch to submit a regulatory application to the FDA for external use sooner than would be possible by solely relying on the premarket approval application ("PMA") pathway. The Company still plans on taking the products being developed for internal use through the PMA process. The ability to employ the 510(k) regulatory pathway for an external use product has been an important development, and it may significantly shorten the timeframe for obtaining regulatory allowance to market a product in the US, which potentially presents a significantly greater commercial opportunity compared to Europe.
Dr. Norchi indicated that in Europe, the Company continues to work with its supply chain partners to complete the obligations required to submit an application for a CE Mark. The Company is also evaluating the impact from recent changes to the European Medical Device Regulations on the timing of a CE Mark filing and approval and, in particular, the degree to which these recent changes may affect the Company's ability to submit a CE Mark application in 2017 as previously announced. Arch anticipates providing a further update when a definitive filing date is determined and plans to file for such approval as soon as reasonable and possible.
Norchi added, "In addition, the Company has made progress on its preclinical pipeline, which includes several product applications with high unmet medical needs. These include applications for chronic cutaneous wounds, burns, surgical adhesions, gastrointestinal anastomoses and ophthalmology.
"Arch was also recently notified that the Japanese Patent Office issued a favorable trial decision to maintain in its entirety an issued patent that had been disputed and which we previously exclusively licensed from the Massachusetts Institute of Technology."
Dr. Norchi concluded, "We believe that our current cash on hand will meet our anticipated cash requirements into the third quarter of Fiscal 2018."
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
FRAMINGHAM, MA -- (Marketwired) -- 05/22/17 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the LD Micro Invitational, which will take place from June 6-7, 2017 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
Chief Executive Officer, Terrence W. Norchi, is scheduled to provide a corporate update on Tuesday, June 6, 2017 at 9:30 AM PT (12:30 PM ET). Dr. Norchi will be available to meet with investors who are registered to attend the conference. If you are an investor and wish to attend the Company's presentation or schedule a meeting, please click the following link: https://www.ldmicro.com/events.
You may access the live webcast by visiting: http://wsw.com/webcast/ldmicro12/arth. The presentation will be available for download at: http://ir.archtherapeutics.com.
Correct: 560,297 shares traded as of 9:06 Central.
BK, what do you consider a moderate move for ARTH when CE happens? Thanks.
Thanks, bb. I too appreciate your insights.
Why, Keith?
Interesting, but:
Press Release - 09/15/2016
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
FRAMINGHAM, MA -- (Marketwired) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced it will be featured as a presenting company at the 2016 Aegis Capital Growth Conference. The presentation will take place at 1:00 PM PDT (4 PM EDT) on Wednesday, September 21st at The Encore at Wynn in Las Vegas, Nevada.
Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide an update on the Company and be available to participate in meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.aegiscapcorp.com) to register for the Aegis conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
A live webcast of the presentation may be accessed by visiting http://wsw.com/webcast/aegis3/arth. Additionally, the presentation will be made available for download at http://ir.archtherapeutics.com.
Thank you, BK.
BK, then you believe the ARTH share price will remain relatively flat for the remainder of 2016?
Thanks.
Agreed. Thanks to all who contributed.
Daubers, I have no idea, butt I'm sure TheHound can answer the question.
New investor in ARTH as of last Friday. Thank you for this.
Nice to hear from you, gov. Hope you are well.
Weely? Why you say dat?
Company's website has been updated to reflect today's news:
http://cellceutix.com/team/
Arthur P. Bertolino, MD, PhD, MBA - President and Chief Medical Officer
Dr. Bertolino is a leading pharmaceutical executive with over fifteen years of domestic and international drug development and management experience. In his career, Dr. Bertolino held several key positions at Novartis Institutes for Biomedical Research (NIBR), including Vice President of Dermatology and Vice President & Global Head of Translational Medicine for Dermatology. During his time at NIBR, Dr. Bertolino was integral to the marketing approval of Ilaris® (canakinumab) in the United States, European Union and Switzerland. He also led the early clinical program of Cosentyx™ (secukinumab) and late stage supportive submission studies.
Dr. Bertolino held positions as Senior Medical Director and Senior Director of Dermatology at Pfizer, Inc. Among other accomplishments at Pfizer, he led clinical programs for over a half-dozen new chemical entities involving Phase 1 and Phase 2 studies and contributed to planning for Phase 3 studies. Dr. Bertolino led FDA clinical interactions at entitlement meetings for Pfizer’s dermatology products and served as Pfizer’s dermatology spokesperson.
Dr. Bertolino served as Chief Medical Officer and Vice President of Medical Affairs at Peplin, Inc., where he led Phase 2 programs and designed and drove initial Phase 3 programs that contributed to FDA approval of Picato® (ingenol mebutate). Dr. Bertolino also held the position of Executive Vice President and Chief Medical Officer at Revance Therapeutics, where he, among other responsibilities, supervised all aspects of clinical staff and programs and regulatory affairs.
Dr. Bertolino earned a BS in Chemistry/Biochemistry from SUNY Stony Brook, an MD and PhD in Pharmacology from The Johns Hopkins University School of Medicine, and an MBA from the University of Michigan Stephen M. Ross School of Business. He has authored over 50 abstracts, papers, and book chapters, and also has been a contributor to major media broadcasts and print media, such as Nightline, Nova, CBS This Morning, Men’s Health, GQ, Discover and more.
Thanks, Karin. Received mine too.
Karin, probably of the last six company e-mails, I've only received four. Must be a glitch somewhere. But I too haven't received today's e-mail -- yet.
Cellceutix shareholder's e-mail from 06/10/2016:
I want to wish everyone a happy and safe weekend and quickly share some thoughts. I must first say “congratulations” to all of us for the court’s ruling to grant our motion to dismiss the Rosen lawsuit; justice was truly served (I’ll add that we’ll be looking for additional justice). The fact is that the lawsuit hurt our reputation and hamstringed us. That said, although the public may not understand it, we’re stronger than ever with the results from the Phase 2 trial of Prurisol and advancement of the rest of our pipeline. We’re always in contact with major pharmaceutical companies and the recent developments have certainly generated significant interest. Of course, nothing in that regard is guaranteed, but we’re optimistic going forward. We’re taking several key steps to grow our company for which I will soon provide a comprehensive update, including our initiative to add experienced personnel with a track record of success to our staff.
In short, I personally enter the weekend invigorated by the latest developments and hope that all of you are as well.
Thank you for your unwavering support.
Cellceutix
In response to Rdunn88:
cyber,
Are you referring to today's new filing by Sullivan? If so, no PR has been released yet re. the filing, has it?
Perhaps we should just wait patiently for a company PR?
Agreed. But Leo can only buy shares that the CTIX sales dept. offers him, I think.
eric, based upon?
Did anyone not receive today's PR via company e-mail? I didn't; just curious if others may have been missed too.
Yes. June 7, 1:00 P.M. (Track 3):
http://www.events.ldmicro.com/agenda/